GLP-1 2.0: The Next Generation of Obesity Drugs
By Dr. Frank (Dr. Francis Yap) · One Day Media Network · Updated September 29, 2026 · Data current to this date
Quick Answer
"GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition, and lower prices. As of September 29, 2026, no next-generation injectable is approved yet: retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD.
Contents
- What "GLP-1 2.0" means
- The 2026 landscape at a glance
- Retatrutide: the triple agonist
- Pills: Foundayo and the Wegovy pill
- Wegovy HD: the 7.2 mg dose
- The amylin wave: CagriSema, zenagamtide, eloralintide
- Survodutide: glucagon and the liver
- MariTide: the monthly injection
- How to read the headline numbers
- Safety and open questions
- Access, cost and the grey market
- What to watch next
- Evidence tiers (CEBM)
- FAQ
- AI personalization guide
- Sources
1. What "GLP-1 2.0" means
The first wave gave us semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound): weekly injections that deliver roughly 15% and 20% average weight loss in pivotal trials.
.png "GLP-1 2.0")
The second wave is defined by five shifts:
- Potency: adding a third hormone (glucagon) to GIP and GLP-1, as retatrutide does.
- New mechanisms: amylin agonists (cagrilintide, eloralintide, zenagamtide) and glucagon co-agonists (survodutide) that act on satiety and energy expenditure differently from GLP-1 alone.
- Format: daily pills now, and once-monthly injections (MariTide) in late-stage trials.
- Quality of weight loss: attention to visceral fat, liver fat and lean mass, not only the scale.
- Price and access: cash-pay prices have fallen and small-molecule pills are cheaper to manufacture than peptides.
2. The 2026 landscape at a glance
Read with caution: the weight-loss figures below come from different trials, durations, populations and statistical estimands. They are not head-to-head comparisons. See Section 9.
| Drug (company) | Mechanism / format | Best reported mean weight loss | Status, Sept 29, 2026 | Tier |
|---|---|---|---|---|
| Retatrutide (Lilly) | GIP + GLP-1 + glucagon; weekly injection | 28.3% at 80 wk (12 mg); 30.3% at 104 wk in BMI ≥35 extension | Phase 3 complete; BLA planned Q1 2027 | 2 |
| Foundayo / orforglipron (Lilly) | Small-molecule GLP-1; daily pill | Up to 11.2% at 72 wk (ATTAIN-1) | FDA-approved Apr 1, 2026 | 1–2 |
| Wegovy pill (Novo Nordisk) | Oral semaglutide; daily, fasting | 13.6% mean in trial data reported at approval | FDA-approved Dec 2025 | 1–2 |
| Wegovy HD (7.2 mg) (Novo Nordisk) | Semaglutide, higher dose; weekly injection | 20.7% at 72 wk (efficacy estimand) | FDA-approved Mar 19, 2026 | 1–2 |
| CagriSema (Novo Nordisk) | Amylin + GLP-1 combination; weekly injection | 23.0% at 84 wk vs 25.5% for tirzepatide (head-to-head) | Under FDA review; decision expected late 2026 | 2 |
| Survodutide (Boehringer / Zealand) | GLP-1 + glucagon; weekly injection | Up to 16.6% (efficacy estimand); 13.0% (treatment-regimen, NEJM) | Phase 3 readouts reported; not yet filed | 1–2 |
| MariTide (Amgen) | GLP-1 agonist + GIP antagonist; monthly or less | About 16–20% at 52 wk (Phase 2) | Phase 3 (MARITIME) ongoing | 3 |
| Eloralintide (Lilly) | Selective amylin agonist; weekly injection | 20.1% at 48 wk (Phase 2) | Phase 3 started Feb 2026 | 3 |
| Zenagamtide (formerly amycretin) (Novo Nordisk) | GLP-1 + amylin in one molecule; oral and injectable | About 22–24% (early trials) | Phase 3 | 3 |
3. Retatrutide: the triple agonist
Retatrutide activates the GIP, GLP-1 and glucagon receptors. The glucagon component is thought to raise energy expenditure and fat oxidation on top of the appetite effects of GIP and GLP-1.
Efficacy
- TRIUMPH-1 (n=2,339, obesity or overweight without diabetes, 80 weeks): mean weight loss was 19.0% (4 mg), 25.9% (9 mg) and 28.3% (12 mg) versus about 2% on placebo. At 12 mg, 45.3% of participants lost ≥30% of body weight. In a pre-specified extension for people with BMI ≥35, average loss reached 30.3% at 104 weeks. Source: Lilly press release, May 21, 2026.
- TRIUMPH-4 (knee osteoarthritis, 68 weeks): 28.7% weight loss at 12 mg with large reductions in knee pain scores.
- TRIUMPH-2 (obesity with type 2 diabetes): up to 20.8%. TRIUMPH-3 (obesity with cardiovascular disease): up to 22.6%. Weight loss is consistently lower when diabetes is present, as with other incretin drugs.
Safety signals
- Discontinuation for adverse events in TRIUMPH-1: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) versus 4.9% on placebo. TRIUMPH-4 saw 18.2% at 12 mg.
- Dysesthesia (abnormal skin sensations such as tingling or hypersensitivity) was reported in about 12.5% at 12 mg in TRIUMPH-1 and 20.9% in TRIUMPH-4, versus about 1% on placebo. Most cases were reported as mild to moderate. Its long-term course is not yet known.
- Gastrointestinal effects (nausea, diarrhea, constipation, vomiting) are the most common and cluster during dose escalation, as with the whole class.
Timeline
Lilly's Q2 2026 report states the clinical data package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, with a Biologics License Application planned for Q1 2027 (Lilly Q2 2026 release). Realistic US approval is therefore no earlier than late 2027, unless the FDA grants an expedited voucher. The cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) is not expected to read out until roughly 2028–2029 according to third-party trackers.
4. Pills: Foundayo and the Wegovy pill
Two oral GLP-1s are now approved for weight management in the US. They are the first products of the "2.0" era that patients can actually receive.
- Wegovy pill (oral semaglutide) was approved in December 2025. It is a peptide and must be taken fasting each morning. Trial data cited at approval showed a mean 13.6% weight loss.
- Foundayo (orforglipron) was approved on April 1, 2026. It is a non-peptide small molecule that can be taken at any time of day without food or water restrictions. In ATTAIN-1, weight loss was dose-dependent, up to 11.2% at 72 weeks, with 71.8% reaching ≥5% loss at the top dose. Lilly announced self-pay prices from $149 to $349 per month depending on dose. Lilly has submitted orforglipron for type 2 diabetes. See NPR's coverage of the approval.
Where pills fit: lower average weight loss than the best injectables, but no needles, no cold chain and cheaper manufacturing. Lilly's leadership has described maintenance after injectable weight loss as a likely role, and a Phase 3 trial in people switching from injectables to orforglipron supported weight maintenance.
5. Wegovy HD: the 7.2 mg dose
On March 19, 2026 the FDA approved Wegovy HD (semaglutide 7.2 mg weekly), the first GLP-1 approved under the FDA's Commissioner's National Priority Voucher pilot. In STEP UP (72 weeks), mean weight loss was 20.7% on the efficacy estimand, with about one in three participants losing ≥25%; in people with type 2 diabetes (STEP UP T2D) it was 14.1%. Safety was described as comparable to lower-dose semaglutide. The EMA's committee issued a positive opinion for a single-dose 7.2 mg pen in May 2026. Source: Novo Nordisk filing, March 19, 2026.
6. The amylin wave: CagriSema, zenagamtide, eloralintide
Amylin is a satiety hormone co-secreted with insulin. Amylin agonists slow gastric emptying and reduce appetite through pathways distinct from GLP-1, which is why they are being paired with or built into GLP-1 drugs.
- CagriSema (cagrilintide + semaglutide): Novo submitted an FDA application on December 18, 2025, with a decision expected in late 2026. But in February 2026 the head-to-head trial against tirzepatide (REDEFINE 4) missed its primary endpoint: 23.0% versus 25.5% at 84 weeks. In type 2 diabetes (REIMAGINE 4), CagriSema was non-inferior to tirzepatide for weight but not for HbA1c. Novo is now testing a higher CagriSema dose. Sources: Novo Nordisk filing; Clinical Trials Arena.
- Zenagamtide (formerly amycretin): a single molecule with both GLP-1 and amylin activity, in oral and injectable forms, now in Phase 3. It is a different molecule from CagriSema; the two should not be conflated.
- Eloralintide (Lilly): a selective amylin agonist that produced 20.1% weight loss at 48 weeks in Phase 2. Phase 3 (ENLIGHTEN-1) began in February 2026 with an estimated primary completion in March 2028 (ClinicalTrials.gov NCT07321886).
7. Survodutide: glucagon and the liver
Survodutide combines GLP-1 and glucagon receptor agonism. In SYNCHRONIZE-1 (n=725, 76 weeks, no diabetes) the sponsor's headline was up to 16.6% weight loss versus 3.2% on placebo, but that is the efficacy estimand (people who stayed on treatment). The peer-reviewed NEJM paper reports −13.0% (6.0 mg) and −12.2% (3.6 mg) versus −5.4% on placebo on the treatment-regimen analysis. Placebo weight loss was higher than planned, partly because some participants who stopped placebo used GLP-1 drugs.
The distinctive finding is organ-level: up to a 34% reduction in visceral fat with limited lean-mass loss, and in SYNCHRONIZE-MASLD, liver-fat normalization in about 6 of 10 participants. Survodutide may therefore find its niche in obesity with fatty liver disease. See Boehringer Ingelheim's results summary.
8. MariTide: the monthly injection
Amgen's maridebart cafraglutide is an antibody-peptide conjugate that activates the GLP-1 receptor while blocking the GIP receptor, designed for dosing monthly or even less often. Phase 2 showed roughly 16–20% weight loss over a year. The MARITIME Phase 3 program (obesity with and without type 2 diabetes, cardiovascular outcomes, heart failure, sleep apnea) is ongoing, and Amgen has been adding type 2 diabetes trials in 2026 (Amgen Q2 2026 release). Approval before about 2028 is unlikely.
9. How to read the headline numbers
- Efficacy vs treatment-regimen estimand. The efficacy estimand (sometimes called "if everyone adhered") is always higher than the treatment-regimen estimand, which counts people who stopped the drug. The survodutide gap (16.6% vs 13.0%) shows how large this can be.
- Population matters. Weight loss is lower in type 2 diabetes and higher in people with higher starting BMI. The 30.3% retatrutide figure applies to a BMI ≥35 subgroup at two years.
- Duration matters. 48-, 68-, 72-, 76- and 80-week trials are not interchangeable.
- Toplines are press releases. Most 2026 readouts are company toplines or conference presentations. Full peer-reviewed data can differ in emphasis.
- Placebo arms move. As survodutide showed, placebo weight loss can drift upward when GLP-1 drugs are widely available.
10. Safety and open questions
- Tolerability ceiling. More potent drugs tend to cause more GI effects and more discontinuations at top doses (retatrutide 12 mg: 11.3%).
- Dysesthesia. A skin-sensation signal that is more prominent with retatrutide; regulators will weigh it in labeling.
- Class warnings. Injectable GLP-1s carry a boxed warning about thyroid C-cell tumors in rodents; pancreatitis, gallbladder disease and (for semaglutide) rare eye events under investigation remain part of the class conversation.
- Lean mass and muscle. Larger weight loss raises questions about muscle, bone and nutrition. Survodutide's body-composition data are reassuring but not definitive.
- Durability. No 2.0 drug has more than about two years of pivotal data. Weight regain after stopping is well documented for semaglutide and tirzepatide, and whether new agents or monthly dosing change this is unproven.
- Cardiovascular outcomes. Semaglutide and tirzepatide have outcome evidence; retatrutide, CagriSema and MariTide do not yet.
11. Access, cost and the grey market
Cash-pay prices have fallen sharply in 2026 through manufacturer direct-to-consumer programs, and Lilly reported a 13% fall in realized prices in Q2 alongside 60% volume growth. Pills start at $149 per month self-pay for the lowest dose. Insurance coverage remains uneven.
A caution on "research" retatrutide: because retatrutide has no regulatory approval anywhere, any vial sold online or by a compounder today is unapproved. Its identity, dose, sterility and purity cannot be verified, and the long-term safety of doses used outside trials is unknown. If you are interested in retatrutide, ask a licensed clinician about approved alternatives or search ClinicalTrials.gov for enrolling studies.
12. What to watch next
| When | Event |
|---|---|
| Late 2026 | FDA decision on CagriSema |
| 2026–2027 | FDA decision on orforglipron (Foundayo) for type 2 diabetes; higher-dose CagriSema (REDEFINE 11) readout |
| Q1 2027 | Retatrutide BLA submission (Lilly guidance) |
| 2027 | Retatrutide head-to-head and maintenance trials; possible survodutide filings |
| ~2028 | MariTide and eloralintide Phase 3 completions; retatrutide outcomes trial begins reporting (2028–2029) |
| Before 2030 | Possible zenagamtide launch (Novo Nordisk executive projection) |
13. Evidence tiers (CEBM)
| Tier | Meaning | Applies to |
|---|---|---|
| 1 | Peer-reviewed RCT(s) or regulatory approval on RCT data | Wegovy HD, Wegovy pill, Foundayo; survodutide SYNCHRONIZE-1 (NEJM) |
| 2 | Phase 3 RCT results via company topline or conference, full paper pending | Retatrutide TRIUMPH program; CagriSema REDEFINE/REIMAGINE |
| 3 | Phase 2 or early-phase trials; efficacy projections | MariTide, eloralintide, zenagamtide |
| 4–5 | Observational data, expert opinion, mechanism | Long-term durability, lean-mass, real-world safety claims for all 2.0 drugs |
14. Frequently asked questions
What does GLP-1 2.0 mean?
The second wave of obesity drugs that build on semaglutide and tirzepatide: multi-hormone agonists, amylin-based drugs, oral and monthly formats, and higher-dose versions of existing drugs.
Is retatrutide FDA approved?
No. It is investigational. Lilly plans to submit its FDA application in the first quarter of 2027.
How much weight did retatrutide cause people to lose?
In TRIUMPH-1, 28.3% at 80 weeks on 12 mg (versus about 2% on placebo), and 30.3% at 104 weeks in the BMI ≥35 extension. Lower in diabetes (up to 20.8%) and cardiovascular disease (up to 22.6%).
Are there GLP-1 pills for weight loss?
Yes: the Wegovy pill (December 2025) and Foundayo (April 1, 2026). Both average less weight loss than the best injectables.
Did CagriSema beat tirzepatide?
No. It produced 23.0% versus 25.5% at 84 weeks in a head-to-head trial and missed its primary endpoint. It remains under FDA review.
Is it safe to buy retatrutide online?
Products sold before approval are unregulated, so their contents and dose cannot be verified. Discuss approved options or clinical trials with a licensed clinician.
Are GLP-1 drugs safe long term?
Current evidence from clinical trials shows no major safety signals in the short to medium term, but long-term data beyond 10 years are still limited.
What is the future of obesity treatment?
The future involves multi-hormonal combination therapies and body composition-focused treatments rather than single-drug weight loss approaches.
15. AI personalization guide
You can use an AI assistant to prepare for a clinician visit. Paste this article and try prompts like the ones below. AI tools can be out of date on fast-moving drug news, so always check dates and primary sources.
- Claude: "Using this article, list the questions I should ask my doctor about switching from semaglutide to a pill for weight maintenance, and flag which claims are Tier 2 or 3."
- ChatGPT: "Make a one-page comparison of approved versus investigational obesity drugs from this article, with the estimand caveats noted."
- Gemini: "Summarize the main safety differences between the drugs here, and tell me what long-term data are still missing."
16. Sources
- Eli Lilly: TRIUMPH-1 press release (May 21, 2026)
- Eli Lilly: Q2 2026 results (August 5, 2026)
- Eli Lilly: FDA approval of Foundayo (April 1, 2026)
- Novo Nordisk: Wegovy HD approval (March 19, 2026)
- Novo Nordisk: CagriSema REIMAGINE 4 and pipeline update
- Clinical Trials Arena: CagriSema vs Zepbound (February 2026)
- Boehringer Ingelheim: SYNCHRONIZE-1 and SYNCHRONIZE-MASLD
- Amgen: Q2 2026 results (MariTide program)
- ClinicalTrials.gov: eloralintide Phase 3 (NCT07321886)
- NPR: FDA approves Foundayo
- GLP-1 Muscle Loss: How to Preserve Lean Mass, Strength & Metabolic Health
- GLP-1 Side Effects & Safety 2026: Emergency vs Urgent Symptoms
- Best GLP-1 for Weight Loss 2026
- GLP-1 Nutrient & Nutrition Guide
- GLP-1 Safety & Long-Term Evidence Guide
- 12 Best Natural Ozempic Alternatives 2026 (Resource Guide)
- Drop the pounds with needle-Free GLPs.
- Low-dose, oral, dissolvable tablets to support your weight loss goals.
- Supports fullness and reduced calorie intake
- Needle-free alternative to injectable options
- 10 mg tablets compounded without artificial colors or dyes.
.png)
.png)
.png)
Comments
Post a Comment